

ersonal use only



DRIVING A NEW PARADIGM IN
BREAST CANCER DIAGNOSTICS



2 MAY 2024

JMM & ETHICA CAPITAL- Innovation & Investment Insights

Jayne Shaw

IMPORTANT NOTICE AND DISCLAIMER



This presentation (Presentation) has been prepared by BCAL Diagnostics Ltd ABN 51 142 051 223 (BCAL or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this Presentation is subject to change without notice and, subject only to any legal obligation to do so, BCAL does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain “forward-looking statements”. The words “forecast”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of BCAL, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to BCAL as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of BCAL, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than BCAL has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, BCAL (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in BCAL or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire BCAL securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of BCAL and the impact that different future outcomes may have on BCAL. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. BCAL is not licensed to provide financial product advice in respect of its securities or any other financial products.



ersonal use only

COMPANY METRICS

ASX Code

BDX

Share Price
12 April 2024

\$0.10

Shares on Issue

252M

Unlisted Options

4.5M

Cash
31 March 2024

\$3.3M

Top 20 Shareholders

57%

COMPANY OVERVIEW




BREASTEST[®]
a blood test
that detects
breast cancer

- Founded in 2010, BCAL Diagnostics is focused on **transforming early detection and screening for breast cancer** for women worldwide with the introduction of its innovative blood test **BREASTEST[®]**
- **Over 5,000 prospective blood samples** have been collected by BCAL to drive test development and machine learning **AI algorithms**
- **Commercial launch in Australia in late 2024 and USA entry in 2025**
- **BREASTEST[®]** will be introduced initially as an adjunct to the current standard of care
- **Highly experienced leadership team** with a strong track record of success, and a network of Key Opinion Leaders (KOLs) to propel market entry

{ **BREASTEST[®]** is *game changing technology* for women in breast cancer screening. }

COMMERCIAL PATHWAY

A 3-year roadmap to saving lives underpinned by a reproducible lipidomic platform and a proprietary biobank of growing data.



01 Australian Launch

- Launch of BREASTEST® in Australia late 2024 & first revenues
- Initial focus on NSW & Victoria where we already have a strong footprint
- Accelerate education & awareness with Breast Surgeons, Breast Clinics, GP's, radiology and pathology providers, Breast care Nurses, Advocacy Groups, and Government agencies
- Develop and implement strategic partnerships to expedite mass market penetration

02 Scale nationally

- Nationwide market access initiatives to take BREASTEST® across Australia
- Define and initiate market entry strategy for US commercial launch
- Expand patient sample processing capacity of Sydney lab
- Grow the revenue with increased market access

03 Globalise

- Publish in scientific literature the clinical and utility performance of BREASTEST® to underpin other market launches
- Secure government funding for BREASTEST® in Australia
- Prepare for commercial launch in the US
- Expand intended use and develop products on BCAL's platform for other cancers
- Consolidate and continue to grow volume in Australia

A GLOBAL COMMERCIAL OPPORTUNITY

Breast cancer is the world's most prevalent cancer in women

WCRFI

13% of

women in the US will develop an invasive form of breast cancer in their lifetime

2024, BreastCancer.org

\$2.3B

2023 to

\$6.9B

2033

Persistence Market Research

On average

57 People

are or will be diagnosed with breast cancer everyday

BCNA

2.1 Million Mammograms in 2021 in AUS

BSA

310,720

cases of breast cancer are expected to be diagnosed in the US in 2024

2024, American Cancer Society

Women have a

1 in 7

chance of being diagnosed with breast cancer over their lifetime

NCBF

\$70M

USD 2024 to

\$108M

2029

Mordor intelligence

52.3 Million Mammograms in 2019 in the US

CDC

Breast Screening – Mammogram

Current Standard of Care

28%

(>20,000) of all new cancer cases in AU women will be breast cancer and **>3000 die from this disease each year**

BCN
A

40+

Guidelines limit access to routine screening to those over 40 years old

health.gov

2.1M

Mammograms occurred in Australia in 2023

AIH
W

42%

of eligible women in Australia **do not get screened:**

BreastScreen Australia

New data from the USA points to a

42% reduction

in mortality if annual screening introduced


<https://pubs.rsna.org/doi/10.1148/radiol.232658>

Current program limitations:

Breast density & old technology leading to high recall rates and false positives, patient experience, Mammogram only recommended every second year due to radiation dose/cost.

BREASTEST® WILL BE USED AS A SCREENING TOOL

ersonal use only



A LIPID BLOOD TEST WITH AUTOMATED ANALYSIS

A LIPIDOMIC PLATFORM THAT INCORPORATES AI MACHINE LEARNING AND LEVERAGES ROBUST SCIENTIFIC RESEARCH

~\$300

Proposed cost of test to the patient, following independent research and focus group

BREASTEST®

AT COLLECTION CENTRE



Blood collection



Whole Blood



Plasma
Erythrocytes


Pre-processing: sample spin, separate and freeze

TRANSIT




Sample preparation:
plasma lipid extraction

AT TESTING LABORATORY



Sample Analysis: Extracts analysed using Liquid Chromatography Mass Spectrometry (LCMS)



Data analysis for breast cancer lipid signatures (presence or absence)

Logistics & processing scaling confirmed

COMMERCIAL LAUNCH ON TRACK FOR **LATE 2024**

Commercial strategy to advance relationships with existing partners to launch BREASTEST® in specialised clinics with first revenues expected to be delivered immediately following launch.

	APR '24	MAY '24	JUN '24	JUL '24	AUG '24	SEP '24	OCT '24	NOV '24	DEC '24	JAN '25
BREASTEST® launch										
First Revenues										
BCAL research published in high profile journal										
BCAL presenting research at BCT, Leura International BCC, CoBrCa Edinburgh, SABCS USA.										
Australian clinical validation study										
Indian clinical study commences & completes										
BCAL signs agreements to collect patient samples with two healthcare providers in USA										
Execute commercial agreements with radiology providers										
Achieve NATA accreditation										
Formalise strategic partners to complete clinical validation study										
Receipt of BREASTEST® and BCAL Dx® trade marks										



ersonal use only

BCAL IS WORKING WITH CLINICIANS FROM LEADING CENTRES **AROUND THE GLOBE**

COMPREHENSIVE
breast care



Endeavor Health.

PRECISION



A pilot study assessing the feasibility of using the BCAL test for early diagnosis of breast cancer in India



- Lakeview Private Hospital
- Dudley Private Hospital
- Westmead Breast Cancer Institute
- Royal North Shore Hospital
- BreastScreen RPAH

CLINIC ADVISORY BOARD

} Eminent and influential Breast Clinicians form a National Key Opinion Leader & Clinical Excellence Forum to enhance trust, provide advice and inform the BCAL program



Dr David Speakman



Prof Bruce Mann



Dr Corinne Ooi



A/Prof. James French



Prof. Elisabeth Elder



A/Prof. Cindy Mak



Dr Samriti Sood



A/Prof. Gillian Lamoury



Dr Sally Baron-Hay



Dr Mary Rickard OAM

ersonal use only

BREASTEST™ HAS STRONG AND GROWING INTELLECTUAL PROPERTY

Title	IP covered	Jurisdiction	Status	Patent number	Priority date	Expected expiry date
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	AU (AU1)	Granted	AU Pat. No. 2011270968	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	AU (AU2)	Granted, Divisional filing	AU Pat. No. 2016213855	23 June 2010	22 June 2031
Methods related to cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	US (US2)	Pending, Divisional filing	US 17/305,824	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	CA (CA1)	Pending	CA 2,803,865	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	EP (EP1)	Granted	EP Pat. No. EP 2585833	23 June 2010	22 June 2031
Use of fatty acids in methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	EP (EP2)	Granted	EP Pat. No. 3206034	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	EP (EP4)	Pending	EP 21200018.6	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	HK (HK1)	Granted	HK Pat. No. 1180764	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	HK (HK2)	Pending	HK 42022052007.6	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	JP (JP1)	Granted	JP Patent No. 5944385	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	JP (JP2)	Granted	JP Patent No. 6092302	23 June 2010	22 June 2031
Diagnostic signature	Use of plasma lipids as a diagnostic method to detect breast cancer in combination with machine learning algorithms	PCT stage	Pending	AU2023/050389	10 May 2022	10 May 2043
Diagnostic signature	Use of plasma lipids as a diagnostic method to detect breast cancer in combination with machine learning algorithms	AU Provisional	Provisional	2023903491	31 Octo 2023	N/A

*Licensed from University of Louisville Research Foundation Inc. European (EP) jurisdictions covered: DE, GB, FR, IT, NL, ES.

BOARD AND EXECUTIVES



Jayne Shaw
Executive Chair

Successful businesswoman, entrepreneur and co-founder. Previously co-founder and owner of the Sydney Breast Clinic.



Hon Ron Phillips AO
Non-executive Director

Health policy expert, previously Minister for Health in NSW Parliament and co-founder and owner of the Sydney Breast Clinic.



Mark Burrows AO
Independent
Non-executive director

An advocate for early diagnosis of breast cancer and other cancers. International banking expert and has held positions of Chairman and NED of major ASX listed corporations.



Jonathan Trollip
Independent
Non-executive Director

International businessman and lawyer. Many years of experience as NED of large ASX-listed companies.



Dr. John Hurrell PhD
Independent
Non-Executive Director and Consultant

More than 35 years' experience in life sciences & healthcare. Has developed & successfully commercialised multiple products & services as well as managing start up/early-stage companies.



Dr David Darling
Non-Executive Director

David Darling, former CEO of Pacific Edge, brings vast commercial expertise to BCAL with a genetics background and 30+ years experience.



Shane Ryan MBA
Chief Executive Officer

Shane Ryan, former Global SVP of Strategy & Innovation at GenesisCare, with 20+ years in oncology, specializes in breast cancer, excelling in patient care, research, and innovative service models.



Dr Amani Batarseh PhD
Chief Scientific Officer

PhD from Georgetown University, Washington, DC Completed post-doctoral studies at Harvard, McGill and Wollongong Universities. Expert in molecular biology lipidomics and mass spectrometry.



Guy Robertson
Chief Financial Officer &
Company Secretary

A Finance Director/Chief Financial Officer for a number of companies within the Jardine Matheson Group over a period of 16 years. Provides CFO and company secretary consulting services to many large corporations and SMEs.



Alison Cook (Mew), MSc
Quality and Regulatory
Advisor

Management and leadership experience of more than 30 years across the biopharmaceutical, diagnostic and health service sectors. Spent 13 years in senior executive roles at CSL Limited. Consulted widely across the life sciences industry.



Kathy Koskiris BSc. MBA.
Director, Clinical Laboratory
Services

More than 20 years' experience in building and managing clinical laboratories under TGA and US CLIA regulations. Managed CLIA certification for multiple new products, CLEP certification and NATA Accreditation with ISO15189 & NPAAC standards.



Dr Simon Preston
Director Clinical Research

15 years of Research and Development experience across academic and industry roles. Extensive clinical and preclinical experience in both pharmaceutical and diagnostics.

ersonal use only



Thank you

Jayne Shaw
Executive Chair
jshaw@bcaldiagnosics.com

Shane Ryan
Chief Executive Officer
sryan@bcaldiagnosics.com

BCAL Diagnostics Limited
ABN 51 142 051 223
Suite 506, Lvl 5,
50 Clarence Street
Sydney NSW 2000

www.bcaldiagnosics.com